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Men’s views of antidepressant treatment for depression, and their 27 
implications for community pharmacy practice. 28 
 29 
Introduction:  30 
Community pharmacy as a profession, is striving to provide better support for people experiencing mental 31 
health problems such as depression 1. Depression is the fifth leading cause of global disability accounting for 32 
4.2% of global years lived with a disability 2. It can worsen treatment outcomes for co-morbid conditions 3 and 33 
is a risk factor for heart disease 4, 5, suicide 6 and alcohol abuse 7. 34 
Men with depression have worse mortality outcomes compared to women with depression 8, 9. This is somewhat 35 
explained by differences in their navigation of depression. Some men mask symptoms 10 and engage in recovery 36 
hindering behaviors such as delayed help-seeking 11-13 and alcohol abuse 14.  Many men have poorer social-37 
support networks, which has been linked to hindered mental health recovery 15.  Hegemonic masculinity is a 38 
concept that can partially explain these findings. It is a pattern of practices, mainly enacted by men, to 39 
demonstrate or protect one’s masculine status 16.  In western societies stoicism, strength, control, and restricted 40 
emotionality are traits typically characteristic of hegemonic masculinity 17, and though men should not be seen 41 
as a homogenous group, the concept of hegemonic masculinity might help orientate healthcare professionals to 42 
relevant mental health phenomena such as self-stigmatisation in response to a threat to gender status 13, 18, 19.  For 43 
some men, reconstruction of one’s masculinity is part of depression recovery 20.  However, hegemonic 44 
masculinity has nuanced meanings across different individuals, cultures, and contexts 21, 22. 45 
Community pharmacists can support men treating depression, particularly those taking antidepressants. They 46 
routinely interact with these patients, have expertise to address medicine related issues and have good mental 47 
health literacy 23-25. Optimally utilising community pharmacists could also alleviate pressures elsewhere in the 48 
healthcare system 1. Yet men underutilise these professionals 26, 27, and there is little knowledge about what men 49 
taking antidepressants see as the role of the community pharmacist in their treatment journey, or how 50 
community pharmacists can best support them.  51 
From non-gender specific knowledge it is known that antidepressant consultations by community pharmacists 52 
predominantly focus upon medication counselling, as opposed to psychosocial discussions 28. Both community 53 
pharmacists and patients consider the community pharmacist’s contributions in depression care to be around 54 
medication safety and supply, and providing information, particularly around adverse drug reactions 23, 29. 55 
Community pharmacists typically spend more time counselling patients who are newly prescribed 56 
antidepressants compared to those collecting antidepressant refills, and do not tend to proactively counsel these 57 
refill patients 24, 30, 31. Yet antidepressant users desire community pharmacists to proactively provide follow-up 58 
care32. These patients want to capitalise on community pharmacist knowledge but can struggle to know what to 59 
ask32. A suggestion from patients taking antidepressants in a Canadian study was that the community pharmacist 60 
should initiate regular discussions so that important topics could be discussed naturally 24.  61 
Good patient-community pharmacist relations, patient centred care and progressive patient trust can facilitate 62 
pharmacy depression interventions 33-36 and the perception of community pharmacy as a ‘safe space’ 33, 37. 63 
Multifaceted pharmacy interventions for depression have been more successful than just educational 64 
interventions 38, although the results only demonstrated improved antidepressant adherence, not clinical 65 
outcomes. These studies predominantly recruited females, with a median of 70% female participants, therefore 66 
findings are not male specific. Interventions that are sensitive to men and action-focused could be more 67 
beneficial to men with depression 39, 40, yet it is unknown what this means for a community pharmacy context.  68 
A better understanding of how community pharmacists can support men taking antidepressants is important 69 
because, although antidepressants are an effective option for treating major depression 41, there are barriers to 70 
their practical application. These include adverse drug reactions 42, 43, including male-specific complaints (e.g. 71 
erectile dysfunction), poor adherence 44-46, and stigma 42, 43, 47. Understanding such phenomena has improved 72 
patient outcomes in depression 48-50. 73 
Some antidepressant users question the bio-chemical explanations of their condition 48, and the validity of 74 
pharmacological treatment 51. This results in the creation of a moral framework to legitimise their treatment 75 
choice and continuation 52. Taking antidepressants can involve both a decision and meaning making process 53. 76 
For example participants experience conflict over ‘duty to be well’ versus ‘taking the easy way out’. How one 77 
feels about antidepressants can be a constant re-evaluation process 53. There is limited knowledge about men’s 78 
views of taking antidepressants. Studies suggest findings are similar to non-gender specific studies, although 79 
hegemonic masculinity is influential for some aspects 20, 54. Some men felt taking antidepressants compromised 80 
hegemonic masculine traits such as control and autonomy 54. These traits are especially valued by men 55, 56. 81 
Aims of the study: 82 
To explore men’s views around antidepressant treatment, including the influences of hegemonic masculinity, 83 
and consider their perceptions of community pharmacists’ role in their antidepressant treatment. The secondary 84 
aim of this study is to consider what these findings mean for community pharmacy practice. 85 
Method: 86 
This study has a qualitative study design. It has been designed and reported in line with Standards for Reporting 87 
Qualitative Research (SRQR) guidelines 57. The method for data collection was individual semi-structured, 88 
audio recorded interviews. There is an underlying assumption in this study that realities are multiple and socially 89 
constructed in line with a constructivist research paradigm.  90 
A brief interview schedule was developed to address identified gaps in the literature. Key topics were around 91 
men’s views of antidepressants, experiences of the community pharmacy, insights into unmet care needs and 92 
potential improvements (see appendix 1). The interview schedule was piloted prior to use. This involved internal 93 
testing with two researchers experienced in qualitative methods, and field-testing with three males, two of whom 94 
had past experience of taking antidepressants to treat depression. Based on the piloting some changes were 95 
made, for example the word ‘intervention’ was replaced with ‘service’ and a question was added to ensure a 96 
shared understanding between participants and interviewer on the definition of ‘community pharmacist’. A 97 
standardised opening question was used to establish an understanding on participant’s antidepressant history, 98 
and to ease participant into the interview. 99 
Eligible participants were males, fluent in English, aged 18-65 years and prescribed antidepressants to treat 100 
depression, including those treating depression with anxiety. Males under 18 years were excluded since this age 101 
range has unique antidepressant prescribing guidance due to different pharmacokinetics and treatment risk 43. 102 
Those over 65 years were excluded since depression in the elderly can be influenced by factors related to ageing 103 
58. Participants with diagnosed schizophrenia, psychosis or dementia were excluded.  104 
Convenience sampling was used for recruitment. Recruitment (and interviews) occurred from August 2017-105 
November 2018. Recruitment occurred via poster recruitment either at a United Kingdom (UK) University (two 106 
participants), or at five participating UK community pharmacies (three participants), or by the community 107 
pharmacists in these branches identifying and approaching eligible participants who presented in the pharmacy 108 
(nine participants). Recruitment discussions occurred in private areas. For all participants a subsequent 109 
discussion was held with a researcher prior to participation to confirm they met inclusion criteria and they 110 
understood the study. Recruitment occurred till data saturation, which was determined when the last two 111 
interviews produced no new themes. Information power (see Malterud et al 59) was also considered to ‘sense 112 
check’ if data saturation was likely to have occurred. Fourteen participants were recruited in total. A relatively 113 
small number of participants could reach data saturation because the study has a fairly narrow aim, and 114 
participants hold specific knowledge and experiences relevant for this aim. Fourteen participants seemed 115 
reasonable for data saturation to have occurred and passed the ‘sense-check’. The ages of recruited participants 116 
ranged from 26-61 years old. The mean age was 49 years. 117 
Interviews ranged from 39 -71 minutes. The mean duration was 56 minutes. All interviews were conducted by 118 
the same female researcher (SB) who was a qualified pharmacist. This researcher had received extensive 119 
training on interviewing prior to conducting the interviews. The participants were briefed that the interviewer 120 
was a pharmacist, however she was introduced to participants as a ‘researcher’. 121 
Interviews were transcribed verbatim, and analysed using thematic analysis (e.g. see Braun and Clarke 2006 122 
60). NVivo12 was used for analysis. The codes were predominantly coded inductively, however ‘hegemonic 123 
masculinity’ was coded deductively.  Initially, a long list of themes were developed by SB, who organised 124 
themes in the list into a candidate set of super-ordinate categories and sub-themes. A technique described by 125 
Ziebland and McPherson 61 facilitated this process (the one sheet of paper technique). Authors met to discuss 126 
coding and themes, and to explore alternative interpretations. The research team comprised of a community 127 
pharmacist, a social pharmacy professor, and a male researcher with personal experience of depression.  128 
This qualitative study is part of a wider study about developing a complex intervention. Participants were aware 129 
about the nature of this study at the time of interview. Eight participants expressed interest in further 130 
involvement. These eight also partook in member checking, where the researcher invited further contributions 131 
on interviews and the preliminary analysis. 132 
Ethics Approval:  133 
UK Research Ethics Committee and University of Nottingham granted ethical approval [Ref: 17/EM/0264]. All 134 
participants signed a consent form and were offered a £10 voucher for participation. Pseudonyms were used.  135 
Participants agreed their confidentiality could be breached to access a professional (e.g. G.P) if the research 136 
team had safeguarding concerns.  137 
 138 
Results: 139 
Table 1 highlights participant demographics. Fourteen participants were recruited. Nine out of fourteen 140 
participants had used antidepressants for more than one year, five for less than one year, and of those five, three 141 
had prior episodes of depression treated with antidepressants. The men had a mix of employment and 142 
relationship status, yet were predominantly aged 40-60 years and Caucasian.  143 


























































































































P1 59  8 months No*  No * White Unemployed Divorced 
/Single 
Heterosexual 
P2 58  20 years Yes  No+ White Unemployed Divorced 
/Single 
Heterosexual 
P3 46  2.5 years Yes  Yes White Unemployed Divorced 
/unknown 
Heterosexual 
P4 61 11 months Yes Yes White Retired Married Heterosexual 
P5 41 
 
6-7 years Yes Yes White Unemployed Divorced 
/unknown 
Heterosexual 




P7 41  10-15 years Yes No+ White Employed Unknown Homosexual 
P8 43 8-9 years No N/A White Employed Married Heterosexual 
P9 59 6-7 years No N/A White Employed Married Heterosexual 
P10 59 4-5 years Yes No+ White Employed Married Heterosexual 
P11 51  1-2 weeks No N/A White Unemployed Single Heterosexual 
P12 60 4-5 months Yes Yes White Employed Married Heterosexual 
P13 40  1.5 years Yes Yes White Self-employed Married Heterosexual 
P14 26 2 years No N/A White 
(Other) 
Employed Married Heterosexual 
* = Prior course prescribed but never started., + = 1 episode, but different antidepressants used.  ++ = Ethnicity descriptors based on classifications from 18 145 
ethnic groups recommended for use by England and Wales government 62.   146 
Antidepressant’s attributions to benefits. 147 
All of the men in this study identified an improvement in their functioning when taking their current 148 
antidepressants. 149 
P7:Those really dark, horrible, awful thoughts. I have considerably less when taking the 150 
medication. 151 
Yet some were uncertain as to what extent these improvements were attributable to antidepressants.  152 
P1: I would like to think, and I'm sure it is, that the tablets must've been kicking in that gave 153 
me the motivation to go out and go running, but I don't know you see that’s it. I don’t know if 154 
it was. 155 
Most men tolerated this uncertainty. It however became problematic when they were considering stopping. 156 
Some men stopped antidepressants to ascertain if they could function without them. 157 
Researcher: What was your reasoning for weaning yourself off? 158 
P10: Because I thought that… I'm not a great fan of taking medication that is not 159 
necessary and the only way to know if it is not necessary…  160 
Many men had unsuccessful withdrawal attempts. They spoke of suddenly feeling “flat” or “awful” and feeling 161 
they must restart antidepressants. They were then unsure how to explain their unsuccessful withdrawals, 162 
potentially attributing it to placebo effects. These experiences made men more cautious about stopping 163 
antidepressants, yet they still reported desiring to do so at some point.  164 
P8: I never know if I can wean myself off or whether I should stay on the level I am on, but to 165 
me I have tried to reduce the amount before and I felt shaky and nervous, whether that is 166 
placebo effect or not I do not know. 167 
Some men sought a discussion with a healthcare professional to ascertain if the dose and/or continuation of 168 
antidepressants was appropriate. If they had not had such a review, this led to feelings such as being “lost in the 169 
system”, “drifting along” or being on their own. 170 
  171 
Views of community pharmacists’ role influences engagement.    172 
Medication supply was seen by participants as community pharmacists’ key role in their depression treatment. 173 
Most accounts highlighted community pharmacists’ dispensing role, and occasions when community 174 
pharmacists had taken an action to ensure participants had medicines, e.g. an emergency supply. There were 175 
some accounts of community pharmacists counselling and supporting participants, which in turn increased a 176 
participant’s confidence in their treatment.  177 
P11:  (the pharmacist) said you will probably see some improvements after a few weeks […] 178 
If somebody encourages me, they say this will help you; people who know what they are 179 
talking about like the pharmacist and the doctor, I do listen to people.  180 
Yet mainly interactions with community pharmacists were sparse and most participants had not sought-out 181 
advice from community pharmacists. 182 
P10: They are just basically a dispenser and it is usually the assistant that hands it out. The 183 
pharmacist you tend never to talk to.  184 
Researcher: Ah-huh. 185 
P10: I have never sought to talk to the pharmacist about it. 186 
These participants did not express dissatisfaction with community pharmacists’ input in their treatment journey; 187 
most were not expecting more. Yet two participants who had a vocational association with the profession felt 188 
more support could have been offered from community pharmacists. 189 
P14:  It just would have felt nice that someone would have concerned themselves with me 190 
[…] It seemed like a very closed interaction. 191 
Some reflected how not understanding the role of the community pharmacist stopped them from discussing 192 
concerns because they were not aware of the option. This was confounded by how they were feeling in their 193 
depressed state, being inclined to keep things in, particularly when they had not previously established a clinical 194 
relationship with the community pharmacist.   195 
P6: It would be really difficult to convince me to have a chat with the pharmacist. Partly 196 
because I did not understand their role, partly because of the mind-set at that point in time. I 197 
guess I have always had a good relationship with my G.P and I did not with my pharmacist 198 
back then. 199 
The physical environment and staff resources were also barriers to sensitive discussions. 200 
P13: There is a till and you talk to someone and everyone’s there […] you can't really say 201 
anything discreetly […] also I would want to know that they have the time. If I can see that 202 
there is 10 people in the queue I am not going to feel like I can have a 10 minute 203 
conversation with them. 204 
If community pharmacists proactively suggested interactions it was felt this could facilitate engagement, yet 205 
participants would need to know community pharmacists had appropriate expertise, resources, and that 206 
interacting with the community pharmacists was in line with collaborative care. One participant (P2) linked 207 
interacting with community pharmacists as “going behind the G.P’s back” believing instead their role in the 208 
U.K’s National Health Service (NHS) model of care system was to supply medication. Alternatively another 209 
participant (P4) referenced how the pharmacy was being advertised as a healthcare resource to utilise and used 210 
that as a justification for engagement. 211 
 212 
Reflection of support and information needs.  213 
Participants spoke about needs to normalise taking antidepressants. This could be done by the pharmacist’s 214 
communication styles. 215 
P13: I think they can help by almost not reacting, certainly not reacting negatively, and 216 
treating you normally and cheerfully, I guess those sorts of approaches means it is not made 217 
a big thing of it normalises it a little bit. 218 
 It could also be done through the information provided, for example participants wanted to know if their dose 219 
was high or low, and therefore what this said about their condition. They also wanted to understand any adverse 220 
drug reactions that would be likely based on their dose, and support on how to interpret information from the 221 
Patient Information Leaflet and the internet based on their dose.  222 
P8: An awareness of the side effects would've been more useful. I was not aware how 223 
clouded my mind would become when I was in a high dosage, that might of been a bit more 224 
useful. 225 
Participants felt the accessibility of the community pharmacists, and their knowledge and skill set, meant they 226 
could help them with these medication support and information needs. Participants also reflected upon struggles 227 
with coming off antidepressants, and mismatched expectations of treatment duration, some initially viewing it as 228 
a ‘quick fix'.  229 
Participants were asked about service ideas or support pharmacies could offer. Most struggled to suggest 230 
developed ideas. Predominantly, ideas focused around improving healthcare access such as hosting 231 
psychological therapy services, or peer support groups at the pharmacy. Alternatively community pharmacists 232 
could organise patient’s access to these services. The reasoning behind why these ideas were suggested was 233 
linked to how easily extra steps to engagement became barriers. 234 
P14: I was signposted to a counselling service or a therapy service, and I had to phone them, 235 
book an appointment, where as if a doctor or a pharmacist has the opportunity to just do that 236 
for me then it would have joined it up better. 237 
Researcher: So what was the issue with you having to speak to them and call up? 238 
P14: You are looking for excuses not to do things.  239 
 240 
 There was a desire for community pharmacists to be another point of contact, being able to triage men who are 241 
struggling, and this was linked to reflections that asking for help could be difficult. Some mentioned gender 242 
sensitive training or services, as there was an awareness that men could perceive threats to masculinity due to 243 
depression. However, equally men did not want to be patronised or stereotyped.  244 
 245 
Hegemonic masculinity and taking antidepressants. 246 
Antidepressants causing benefits was, for some, an assertion that they had not solved their depression 247 
themselves. For them it symbolised a weakness, failure, madness, or dependence upon something.  248 
P13: You feel you need something just to get by, I think it feels like a failure.  249 
These feelings could be problematic with ones masculinity.  250 
P10: Maybe it is a male thing about the perceived strength… I do not need this because I am 251 
a male.  252 
Yet taking antidepressants could be seen as a logical approach, symbolic of taking ownership to solve problems. 253 
One participant symbolised his masculinity by positioning men not taking prescribed antidepressants as not 254 
being masculine. 255 
P3: I was going to say ‘a big…big girls blouse’ well yes stop being a big girls blouse, and 256 
basically pull your finger out and take it. 257 
Influences of masculinity could cause challenges in healthcare interactions. When P9 is asked about his views 258 
about being approached by the community pharmacist to discuss medication he perceives a potential threat to 259 
his masculinity.  260 
P9: I don't know. I honestly could not say because is there a maybe a little bit of stigma 261 
attached ‘oh this bloke has got antidepressants’. 262 
Some men were not used to opening up about their feelings. This caused barriers to discussions around 263 
depression treatment and concerns.  264 
Researcher: Linked to your concerns [about taking antidepressants], were those concerns 265 
you felt that you could ask as a question? 266 
P6: To the pharmacist? 267 
Researcher: To anyone. 268 
P6: Yeah.... no.  269 
Researcher: Ah-huh. 270 
P6: Definitely. 271 
Researcher: Can you describe why that was? 272 
P6: I suspect it was partly a gender thing, although I do not want to generalise too much. I 273 
did feel quite isolated as a man and that men do not really talk about it. 274 
 275 
Influence of cognitive state upon healthcare interactions. 276 
At the point of first being prescribed antidepressants, the men spoke of being focused on obtaining a solution to 277 
their depression. Underlying this focus was a desperation; a feeling they had no choice but to seek treatment. 278 
The men explained that their impaired cognitive state hindered approaches such as gathering information, 279 
deliberation, or exploring concerns relating to antidepressants.  280 
Researcher: You have not used them before, was there any concerns about taking them? 281 
P5: I did not even think about it. 282 
Researcher: Did not think about it. Ah-huh. 283 
P5: Because I did not… I did not feel normal at all. 284 
Exploring concerns could also be seen as counterintuitive to obtaining a solution.  285 
P2: I think I was of a state where I was like just give me something. I am not going to start 286 
quibbling. 287 
One participant presented an analogy to illustrate difficulties in mind-set when one has impaired mental health. 288 
He suggests that, when depressed, one may not make rational, engaged choices; yet when in a healthier mind 289 
one may have more purposeful engagement with treatment once that treatment has shown to facilitate recovery.   290 
P3: Well when you are depressed it is a bit like being dehydrated the last thing you want to 291 
do is drink water when you are dehydrated, but then when you start drinking the water you 292 
get the taste for it and then you force it down, eventually start to get thirsty and you want to 293 
drink water and then obviously become rehydrated again, it is kind of similar.   294 
Participants also spoke of frustration when their initial strategy to take the antidepressants did not result in quick 295 
recovery. This led to feelings of being alone, frustration with the prescriber, the manufacturers of the medicine, 296 
and disbelief in the treatment strategy. Few felt able to express these concerns, instead presenting a front.  297 
P12: The thing with antidepressants is they're not quick enough…Every time they said to me 298 
‘are you going to kill yourself?’ So I thought I’ll say no but it's a bit of a cop-out because you 299 
go around the corner and you think, God I feel awful today. I really feel horrible today, and 300 
I'll wait till everybody's gone to work and then I'll do what I do. 301 
 302 
Discussion: 303 
This is the first study to explore the community pharmacist’s role in antidepressant treatment from the 304 
perspective of men with depression. There is seemingly a disconnect between what participants in this study 305 
view as the community pharmacist’s role within their care, and what the professional body for pharmacy 306 
visualises the community pharmacist’s role to be. Professional bodies advocate for a greater role for community 307 
pharmacists in mental health 1. Yet the findings of this study showed most participants viewed the community 308 
pharmacist’s role to be around safely dispensing their medication, and accounts of the community pharmacist’s 309 
involvement in their care were sparse; a finding also found in studies looking at both genders 63, 64. Participants 310 
did not express dissatisfaction with this, except two participants who had a vocational association with the 311 
profession.  312 
To understand this disconnect, and how it might be changed, key themes are discussed. The first being men’s 313 
cognitive state when first prescribed antidepressants. This study is the first study to give salient voice to men’s 314 
reflections on how their condition impaired their gathering of information, and a decision making process, when 315 
starting antidepressants. The men were focused upon obtaining a solution to their depression. They were 316 
unlikely to have given cognitive space to explore concerns or beliefs, and were not seeking to deliberate and 317 
gather information. In some cases such an approach was likened to being a barrier to obtaining a solution 318 
[starting and/or obtaining antidepressants]. Depression can hinder ones decision making ability, particularly by 319 
impairing deliberation and appreciation of information 65. Many men suffering from depression present to 320 
healthcare professionals at the point of desperation and despair 10. This pattern has been linked to hegemonic 321 
masculinity, where men advocate stoicism or solving depression themselves first, and delay help-seeking until a 322 
point of despair 13, 66. Despair as a phenomenon has been connected to impaired engagement and information 323 
gathering in patients with mental illness 67. Participants also spoke about how they were inclined to keep 324 
concerns in check, and were not used to discussing their mental health. Previous studies have found that men 325 
may be less articulate than women when depressed 14, 68, 69.  326 
Yet this study did find that the men, when reflecting, highlighted unmet information and support needs. Key 327 
initial support and information needs were predominantly around normalising the condition and contextualising 328 
their treatment. Other studies have shown men can self-stigmatise for taking antidepressants 70, 71 and may 329 
undergo a meaning making process, involving cognitive realignment on what it means to take antidepressants. 330 
This study supports this finding and adds that participants can go through a meaning making process upon what 331 
their prescribed dose means in terms of their depression, and how it relates to others. 332 
Another key finding, also shown in mixed-sex studies 72, was the struggle the participants expressed with 333 
knowing when to stop antidepressants. This finding is linked to uncertainty on the extent antidepressants were 334 
causing noticed benefits, and initial unrealistic views of treatment duration. These initial unrealistic views could 335 
go unchallenged as men, due to their cognitive state, were not seeking to verify beliefs. 336 
Men spoke about barriers to community pharmacy interactions. Some barriers found in this study have already 337 
been shown in other literature, such as the physical set up of a pharmacy causing privacy concerns 36 which was 338 
linked to stigma, and concern of antidepressants signifying meaning to others. 339 
An interesting finding was the need for participants to know as a requisite for engagement, that they were 340 
interacting within the community pharmacists’ scope of practice and competency, and as part of the wider NHS 341 
strategy of care. This makes the finding that participants saw the role of the community pharmacists 342 
predominantly as a supplier of medicines all the more pertinent, creating a barrier for unsolicited engagement. 343 
Particularly concerning was that participants could liken turning to community pharmacists for advice as “going 344 
behind the G.P’s back”. 345 
Implications for Community Pharmacy Practice: 346 
Some men may be unlikely to proactively engage with the community pharmacist in discussions around 347 
depression and treatments. Such an approach is not in line with their recovery strategy. Instead pharmacy could 348 
consider ways to facilitate engagement. Men could be educated that discussions around antidepressants, and 349 
wider holistic care is within community pharmacists’ scope of practice and expertise. 350 
It may be particularly important for pharmacy as a profession to seek ways to implement closer collaborative 351 
care with other mental health providers. In the UK community pharmacy access to a patient’s clinical records is 352 
restricted. They can access a patient’s NHS Summary Care Record, yet the accessible information is clinically 353 
limited 73, and collaborative working models between community pharmacists remains minimal 73  a finding also 354 
found in other countries 74, 75. Researchers have recommended that community pharmacy interventions 355 
incorporate strategies to link with prescribers 63, 76. This current study strengthens this recommendation, but also 356 
further expands on it; both the collaborative system, and patients understanding of it need improving. Relevant 357 
healthcare professionals should help patients understand collaborative care behaviour, and improve patient’s 358 
perception of a community pharmacists’ role within a collaborative care model.  359 
Community pharmacists should encourage patients to explore their concerns and beliefs. This is particularly 360 
important since patient beliefs around antidepressants influence adherence 77. Community pharmacists may need 361 
to help participants normalise their condition and treatment. This may include giving information on dose ranges 362 
and if their dose is normal. Community pharmacists should ensure patients are aware of potential side effects of 363 
antidepressants when newly starting, or when having a dose change. Literature shows minimal evidence of 364 
negative impact of such discussions 78. Community pharmacists could reiterate that antidepressants should not 365 
be considered as a “quick fix”, and ask monitoring questions throughout treatment, particularly as some men 366 
feel “lost in the system” when stabilised on the medication. In particular this study found a need for staggered 367 
support over time, and that is where the accessibility of community pharmacists could be particularly useful, a 368 
finding supported by other literature 79, 80. Some participants had unsuccessful attempts at stopping 369 
antidepressants and attributed this to placebo effects. An awareness that patients can hold such views could help 370 
pharmacy practice. Particularly as it is possible such experiences could be linked to withdrawal symptoms, 371 
which can vary in severity and duration between patients 81. Patients should be educated on withdrawal and 372 
managed appropriately.  373 
While this study did not assess adherence it is worth noting all the men were currently taking their 374 
antidepressants and either felt antidepressants improved their mood, or perceived a need to be on 375 
antidepressants. Literature has shown that perceived need for antidepressants can increase adherence, although 376 
only if this outweighs concern on the medication82. Overall it is important for community pharmacists to explore 377 
patient’s views on antidepressant need, highlight the potential benefits of the medication, while also exploring 378 
any concerns as highlighted above.  379 
These findings come from male participants, but not all findings are gender specific. It seems that 380 
antidepressants could challenge masculinity, yet not all men will experience this. Care should be taken not to 381 
patronise or stereotype men as this could be detrimental 40, 83.  Community pharmacists should also be aware that 382 
men when depressed may put on a front, as a strategy to keep concerns in check, and this could be a barrier to 383 
communication.  384 
Translation of these recommendations into routine practice will need careful planning and support from leaders 385 
of the profession as some barriers such as time 23, 29, 84, lack of pharmacists confidence in talking to those with 386 
depression 84-87, and lack of collaboration with physicians 23, 84 need addressing at both an individual and 387 
organizational level 76.    388 
 389 
Limitations of study: 390 
This was a small scale study. Based on the last two interviews producing no new themes it can be said data 391 
saturation was reached, however participants are predominantly Caucasians aged 40-60 years. Therefore it is not 392 
clear how generalizable results are. Further studies focusing on different ethnicities, and those aged 18-25 years 393 
would be beneficial.  394 
The researcher was female and a pharmacist which could have influenced the responses the men gave. Also 395 
most participants were recruited by a community pharmacist and this again could have influenced responses 396 
men gave on topics of community pharmacy. Yet care was given to create rapport and encourage the men to 397 
give full responses, which may have addressed this. 398 
Another issue from recruitment via the community pharmacist is that pharmacists may have recruited those they 399 
knew. However the pharmacist recruiters confirmed they recruited a mix of participants they knew, and those 400 
they did not. Also having varied recruitment routes (e.g. posters) could have decreased this potential bias risk. 401 
Most men gave reflective accounts, and this could be subject to recall bias. This study also reported participants’ 402 
perceptions for how community pharmacists could improve their care and these may not be beneficial in 403 
practice. Some men suggested intervention ideas, yet ideas presented lacked depth and/or explanation of active 404 
components. This is expected since the method in this study facilitates gathering of ideas, but not a systematic 405 
and rigorous approach for intervention development, and results should be interpreted within this context. 406 
Further work around developing gender sensitive pharmacy services using appropriate methods would be useful.  407 
 408 
Conclusion: 409 
Some men, particularly those that adhere to hegemonic masculinity may not seek out consultations with 410 
community pharmacists around their condition or treatment. It is known hegemonic masculinity can delay men 411 
seeking treatment until a point of desperation. This study finds that in this state, they are not giving cognitive 412 
space to explore their information needs nor their underlying views around antidepressants. Most men had not 413 
sought advice from the community pharmacist. Medication supply was seen as the principal role of the 414 
community pharmacist in their care.  415 
It would be beneficial for community pharmacists to create opportunities for men to engage in conversations 416 
around their antidepressants and wider support. If men view such interactions as within community pharmacists’ 417 
scope of practice and expertise, part of a collaborative healthcare system, and not threatening to their 418 
masculinity, then these engagements are more likely to be acceptable to men. Such interactions can be beneficial 419 
at first prescription and also throughout treatment, and discontinuation.  420 
 421 
Appendix.  422 
Appendix 1: Interview guide used in semi-structured interviews.  423 




How long have you been taking your (current) antidepressant?  
Second: Was this the first time you used antidepressant medication? 
General questions: 
 
When you had your new prescription, did you remember having 
any concerns? 
Follow up/Probe: What were they, can you describe further? What specifically 
concerned you? Etc. 
Or if ‘no’ – ask about did they remember having a need for further 
information? 
General questions: Did you ask any questions?  
(or if relevant:) speak about these concerns?   
If 
relevant 
Follow up/Probe: Who did you ask/speak to? What influenced your decision to ask 
this person?  
If ‘yes’ 
General questions: Did you have any concerns that could be easily asked as a question?  
Follow up/Probe: Can you give examples/What were they, can you describe further? 
What specifically makes them easy to ask? Etc. 
General questions: Did you have any concerns that were not easily asked as a question?  If ‘yes’ 
General questions: Can you describe further? What are the challenges to ask these in a 
question form? What makes them not easily asked as a question? 
General questions: When you had your new prescription, did you remember having 
any need for further support? 
 
Follow up/Probe: Can you give example? Etc. 
General questions: 
 
So you have taken your antidepressant medication for xxx long. 
Knowing what you know now, what would be the most important 
question you think someone should ask about when they are newly 
starting antidepressant medication? 
Follow up:  Can you explain further?  
General questions: 
 
Again, knowing what you know now, what would be important 
advice you think someone should be given when they are newly 
starting antidepressant medication? 
 
Follow up:  Can you explain further?  
 And finally, knowing what you know now, what would be 
important support someone should be given when they are newly 
starting antidepressant medication? 
Clarification/Expanding 
question 
Is there anything you want to add or expand upon before I move 
onto new topic? 
Blurb: A focus of this research is understanding how community pharmacy can improve the support they 
offer to patients. In this study I’m focusing upon men with depression. 
 
Before asking question establish a shared understanding with participant on what ‘community pharmacy’ 
means. 
NB: Ask if patient needs/wants a break here (be after approx. 30mins of interviewing) 424 
Introductory Question: You mentioned xxx support needed. Can community pharmacy 
help with providing this support? 
(If relevant) 
Follow up:  How might pharmacy help to provide this for support men 
treating depression? 
Direct Question: What services could pharmacy deliver to better support men 
treating depression? 
 
Follow up:  Can you give further detail on that? Can you explain further? (If relevant) 
Direct Question: Previously we spoke about xxx concerns, information needs and 
support. What current needs in relation to your condition, and 
treating your condition are not being met? 
(If relevant) 
Direct Question: Can pharmacy help meet these needs? (If relevant) 
  425 
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